Revvity
NYSE: RVTY
Stock price
152.16 USD
(-10.48%) 5 years
Financial Performance
5Y price score: (13)
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 178.2%
%
ㅤ
By default your notes are visible only to you.
81.2
52-week range
166.2
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
3.2 %
Dividend Yield TTM
0.2 %
Market cap $
$ 16,975
Price / Earnings TTM
72.5
Price / Book TTM
2.4
PEG TTM
(5.3)
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
66.1 %
(9.7) %
178.2 %
Free cash flow per share growth
64.8 %
(39.3) %
97.6 %
Earnings per share growth
-
(68) %
10.9 %
Founded: 1,937
Employees: 11,000
Business Summary:
Q&A
Contribute
By providing well-researched and detailed answer you increase your chance of becoming Top Contributor. TopFunds is free for all top contributors. Learn more
Latest Earnings Call Takeaways
2026 Q2 (Aug 4, 2026)
1) Strong Financial Performance and Guidance Update
- Revvity reported Q2 2026 total revenue of $711 million, achieving 3% organic growth, exceeding expectations.
- Adjusted EPS was $1.41, surpassing guidance due to operational performance and $16 million in tariff refunds.
- Full-year organic growth guidance raised to 4% to 5% from 3% to 4%; adjusted operating margins expected at 28.7%.
- Adjusted EPS guidance increased to $5.30 to $5.40, reflecting improved revenue and margin outlook.
2) Segment Performance Highlights
- Diagnostics segment grew 11% organically, driven by strong performance in reproductive health and immunodiagnostics.
- Life Sciences segment faced a 3% organic decline, primarily due to a 20% drop in Signals software revenue; however, reagents and instruments showed positive growth.
- High-content screening instruments, particularly the Opera Phenix OptIQ, saw double-digit growth, indicating strong demand in AI-driven workflows.
3) Strategic Initiatives and Market Positioning
- Revvity is divesting its China immunodiagnostics business, with a definitive agreement signed, expected to close by the end of 2027.
- The company is focusing on enhancing its Signals software capabilities, integrating AI functionalities to improve customer workflows.
- New initiatives like Signals for Startups aim to broaden access to Revvity's platform for emerging biotech firms.
4) Operational Efficiency and Cash Flow
- Strong cash flow generation of $184 million in Q2, with a 117% conversion rate of adjusted net income.
- The company retired a EUR 500 million note, targeting a gross leverage ratio below 3x by year-end.
- Continued investment in operational efficiency and strategic initiatives is expected to enhance long-term performance.
5) Market Outlook and Challenges
- Revvity is optimistic about the second half of 2026, citing improved conditions in pharma and biotech markets.
- The company anticipates continued demand for AI-related tools, although the full impact of these trends on revenue is still developing.
- There are challenges related to the timing of instrument deliveries and software contract renewals, which may affect short-term performance.
Bottom line: Revvity's strong Q2 performance and raised guidance reflect a resilient business model, particularly in Diagnostics and high-content screening, positioning the company well to capitalize on emerging AI-driven opportunities in preclinical research.
Annual Reports, Presentations And IR Contacts
Go to the websiteRevvity — Financial Overview, Stock Price, Market Cap
Revvity is a company. Founded in 1937. As of October 9, 2026, the company's market capitalization is $16974969600 with a current stock price of $152.16.